Steripath Clinical & Economic Report

The Clinical & Economic Report summarizes 24 studies on the Steripath® Platform, highlighting its clinical and cost-effectiveness in various healthcare settings. This report highlights key findings that are crucial for hospital leaders invested in improving patient health outcomes at their institution.

Some key takeaways from the report include: 

At the University of Nebraska Medical Center, Steripath Platform reduced blood culture contamination rates by 92%, resulting in an annual cost-saving projection of $1.8 million.

Lee Health reported an 83% reduction in blood culture contamination with Steripath Platform, preventing 184 false-positive events with estimated cost savings of over $640,000 during the 7-month trial period.

Brooke Army Medical Center reduced its blood culture contamination by 90% with Steripath Platform, which also resulted in a significant incremental decrease in vancomycin days of therapy by 31%

Stanford Health Care reported a 100% reduction in blood culture contamination with Steripath Gen2, accompanied by a 12-fold decrease in false-positive CLABSIs.

Plus, peer-reviewed studies from leading journals including: 

• Central Texas Veterans Health Care System 
• Shaare Zedek Medical Center 
• University of Houston (College of Pharmacy) 
• Massachusetts General Hospital, Harvard Medical School, Wing Tech Inc. 
• WVU United Hospital Center 
• And more…   

Steripath diversion principles have been clinically proven to be reproducible and sustainable across major academic teaching institutions; government, military, and VA medical centers; and large and small community hospitals. All studies reported between 75-100% reduction in blood culture contamination and sustained 1% or less blood culture contamination rates using the Steripath® Platform, which is consistent with the 2022 CLSI M47 2nd Edition goal of 1%.

The Clinical & Economic Report demonstrates the Steripath Platform’s ability to reduce blood culture contamination rates, resulting in improved patient outcomes and significant cost savings. To explore these findings in-depth and learn more about how the Steripath Platform can help you reach or exceed your institutions blood culture contamination goals, download the full Clinical & Economic Report today!